Skip to main content
SpringerLink
Log in

Médicaments et grossesse : aide pour l’échographiste

Drugs in pregnancy: a contribution to ultrasound diagnosis

  • Mise au Point / Update
  • Published:
Revue de médecine périnatale

Résumé

L’apport du diagnostic prénatal échographique au suivi de grossesses exposées à des médicaments est capital. Il contribue aux choix thérapeutiques par la mise en adéquation des possibilités techniques, face aux atteintes foetales potentielles provoquées par chaque option thérapeutique envisagée. Il permet également un suivi foetal ciblé lors d’une exposition maternelle potentiellement dangereuse. Et enfin, il contribue à l’enquête étiologique lors de la découverte pré-natale d’atteintes foetales concomitante à une exposition médicamenteuse maternelle.

Abstract

Ultrasound diagnosis is of paramount importance for the management of drug exposures during pregnancy. It participates to therapeutic strategies by determining technical strengths and limitations facing different potential teratogenic consequences of drug treatments. It allows adapted prenatal surveys of exposed mothers, focused on the specific drug induced fetal effects. And it contributes to etiological inquiries facing prenatal diagnosis of birth defects, detecting relationships between fetal adverse effects and maternal drugs exposures.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Références

  1. Elefant E, Beghin D (2009) Le passage transplacentaire des médicaments. Bull Acad Natle Méd 193:1043–1057

    CAS  Google Scholar 

  2. Dolk H, Loane M, Garne E (2010) The prevalence of congenital anomalies in Europe. Adv Exp Med Biol 686:349–364

    Article  PubMed  Google Scholar 

  3. Mitchell AA (2003) Systematic identification of drugs that cause birth defects-a new opportunity. N Engl J Med 349:2556–2559

    Article  CAS  PubMed  Google Scholar 

  4. Elefant E, Boyer P, Roux C (1986) Tératologie. Encyclopédie Médico-Chirurgicale-Obstétrique 5116,1,A-10,3,16 p

    Google Scholar 

  5. Tomson T, Battino D, Bonizzoni E, et al (2011) Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. EURAP study group. Lancet Neurol 10:609–617

    Article  CAS  PubMed  Google Scholar 

  6. Hernández-Díaz S, Smith CR, Shen A, et al (2012) Comparative safety of antiepileptic drugs during pregnancy. North American AED Pregnancy Registry. Neurology 78:1692–1699

    Article  PubMed  Google Scholar 

  7. Campbell E, Kennedy F, Russell A, et al (2014) Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. J Neurol Neurosurg Psychiatry [Epub ahead of print]

    Google Scholar 

  8. DiLiberti JH, Farndon PA, Dennis NR, Curry CJ (1984) The fetal valproate syndrome. Am J Med Genet 19:473–481

    Article  CAS  PubMed  Google Scholar 

  9. Christensen J, Grønborg TK, Sørensen MJ, et al (2013) Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA 309:1696–1703

    Article  CAS  PubMed  Google Scholar 

  10. Bromley RL, Mawer GE, Briggs M, et al (2013) The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs. J Neurol Neurosurg Psychiatry 84:637–643

    Article  PubMed  Google Scholar 

  11. Meador KJ, Baker GA, Browning N, et al (2013) Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurol 12:244–252

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  12. Tomson T, Battino D, Perucca E (2011) Major birth defects after exposure to newer-generation antiepileptic drugs. JAMA 306:826–827

    Article  CAS  PubMed  Google Scholar 

  13. de Die-Smulders CE, Sturkenboom MC, Veraart J, et al (1995) Severe limb defects and craniofacial anomalies in a fetus conceived during acitretin therapy. Teratology 52:215–219

    Article  PubMed  Google Scholar 

  14. Grønhøj Larsen F, Steinkjer B, Jakobsen P, et al (2000) Acitretin is converted to etretinate only during concomitant alcohol intake. Br J Dermatol 143:1164–1169

    Article  PubMed  Google Scholar 

  15. Schaefer C, Hannemann D, Meister R, Eléfant E, et al (2006) Vitamin K antagonists and pregnancy outcome. A multi-centre prospective study. Thromb Haemost 95:949–957

    CAS  PubMed  Google Scholar 

  16. Levaillant JM, Moeglin D, Zouiten K, et al (2009) Binder phenotype: clinical and etiological heterogeneity of the so-called Binder maxillonasal dysplasia in prenatally diagnosed cases, and review of the literature. Prenat Diagn 29:140–150

    Article  CAS  PubMed  Google Scholar 

  17. Nezvalová-Henriksen K, Spigset O, Nordeng H (2013) Effects of ibuprofen, diclofenac, naproxen, and piroxicam on the course of pregnancy and pregnancy outcome: a prospective cohort study. BJOG 120:948–959

    Article  PubMed  Google Scholar 

  18. Daniel S, Matok I, Gorodischer R, et al (2012) Major malformations following exposure to nonsteroidal antiinflammatory drugs during the first trimester of pregnancy. J Rheumatol 39:2163–2169

    Article  CAS  PubMed  Google Scholar 

  19. Koren G, Florescu A, Costei AM, et al (2006) Nonsteroidal antiinflammatory drugs during third trimester and the risk of premature closure of the ductus arteriosus: a meta-analysis. Ann Pharmacother 40:824–829

    Article  CAS  PubMed  Google Scholar 

  20. Van Marter LJ, Hernandez-Diaz S, Werler MM, et al (2013) Nonsteroidal antiinflammatory drugs in late pregnancy and persistent pulmonary hypertension of the newborn. Pediatrics 131:79–87

    Article  PubMed Central  PubMed  Google Scholar 

  21. http://www.afssaps.fr/Infos-de-securite/Lettres-aux-professionnelsde-sante/Rappel-sur-la-contre-indication-des-AINS-a-partir-dudebut-du-6eme-mois-de-la-grossesse-quelle-que-soit-la-voie-dadministration

  22. Paladini D, Marasini M, Volpe P (2005) Severe ductal constriction in the third-trimester fetus following maternal self-medication with nimesulide. Ultrasound Obstet Gynecol 25:357–361

    Article  CAS  PubMed  Google Scholar 

  23. Sawdy RJ, Lye S, Fisk NM, Bennett PR (2003) A double-blind randomized study of fetal side effects during and after the shortterm maternal administration of indomethacin, sulindac, and nimesulide for the treatment of preterm labor. Am J Obstet Gynecol 188:1046–1051

    Article  CAS  PubMed  Google Scholar 

  24. Jentink J, Dolk H, Loane MA, et al (2010) Intrauterine exposure to carbamazepine and specific congenital malformations: systematic review and case-control study. BMJ 341:c6581

    Article  PubMed Central  PubMed  Google Scholar 

  25. Yoshihara A, Noh J, Yamaguchi T, et al (2012) Treatment of graves’ disease with antithyroid drugs in the first trimester of pregnancy and the prevalence of congenital malformation. J Clin Endocrinol Metab 97:2396–2403

    Article  CAS  PubMed  Google Scholar 

  26. Abe M, Syuto T, Yokoyama Y, Ishikawa O (2010) Aplasia cutis congenita after methimazole exposure in utero successfully treated with basic fibroblast growth factor. Int J Dermatol 49:334–335

    Article  PubMed  Google Scholar 

  27. Barbero P, Valdez R, Rodríguez H, et al (2008) Choanal atresia associated with maternal hyperthyroidism treated with methimazole: a case-control study. Am J Med Genet A 146A:2390–2395

    Article  PubMed  Google Scholar 

  28. Andersen SL, Olsen J, Wu CS, Laurberg P (1998) Birth defects after early pregnancy use of antithyroid drugs: a Danish nationwide study. J Clin Endocrinol Metab 98:4373–4381

    Article  Google Scholar 

  29. Di Gianantonio E, Schaefer C, Mastroiacovo PP, et al (2001) Adverse effects of prenatal methimazole exposure. Teratology 64:262–266

    Article  PubMed  Google Scholar 

  30. Lassen PD, Sundberg K, Juul A, Skibsted L (2008) Fetal goiter and bilateral ovarian cysts. Fetal Diagn Ther 23:132–135

    Article  PubMed  Google Scholar 

  31. Aleck KA, Bartley DL (1997) Multiple malformation syndrome following fluconazole use in pregnancy: report of an additional patient. Am J Med Genet 72:253–256

    Article  CAS  PubMed  Google Scholar 

  32. Mølgaard-Nielsen D, Pasternak B, Hviid A (2013) Use of oral fluconazole during pregnancy and the risk of birth defects. N Engl J Med 369:830–839

    Article  PubMed  Google Scholar 

  33. Quan A (2006) Fetopathy associated with exposure to angiotensin converting enzyme inhibitors and angiotensin receptor antagonists. Early Hum Dev 82:23–28

    Article  CAS  PubMed  Google Scholar 

  34. Polifka JE (2012) Is there an embryopathy associated with first-trimester exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists? A critical review of the evidence. Birth Defects Res A Clin Mol Teratol 94:576–598

    Article  CAS  PubMed  Google Scholar 

  35. Spaggiari E, Heidet L, Grange G, et al (2012) Prognosis and outcome of pregnancies exposed to renin-angiotensin system blockers. Prenat Diagn 32:1071–1076

    Article  CAS  PubMed  Google Scholar 

  36. Lammer EJ, Chen DT, Hoar RM, et al (1985) Retinoic acid embryopathy. N Engl J Med 313:837–841

    Article  CAS  PubMed  Google Scholar 

  37. Lee SM, Kim HM, Lee JS, et al (2009) A case of suspected isotretinoin-induced malformation in a baby of a mother who became pregnant one month after discontinuation of the drug. Yonsei Med J 50:445–447

    Article  PubMed Central  PubMed  Google Scholar 

  38. Källén B, Tandberg A (1983) Lithium and pregnancy. A cohort study on manic-depressive women. Acta Psychiatr Scand 68:134–139

    Article  PubMed  Google Scholar 

  39. Jacobson SJ, Jones K, Johnson K, et al (1992) Prospective multicentre study of pregnancy outcome after lithium exposure during first trimester. Lancet 339:530–533

    Article  CAS  PubMed  Google Scholar 

  40. Pinelli JM, Symington AJ, Cunningham KA, Paes BA (2002) Case report and review of the perinatal implications of maternal lithium use. Am J Obstet Gynecol 187:245–249

    Article  PubMed  Google Scholar 

  41. Aftimos S (2009) Fetal methotrexate/aminopterin syndrome in an adult: a likely case with ectodermal abnormalities. Clin Dysmorphol 18:53–55

    Article  PubMed  Google Scholar 

  42. Hyoun SC, Običan SG, Scialli AR (2012) Teratogen update: methotrexate. Birth Defects Res A Clin Mol Teratol 94:187–207

    Article  CAS  PubMed  Google Scholar 

  43. Vauzelle C, Beghin D, Cournot MP, Elefant E (2013) Birth defects after exposure to misoprostol in the first trimester of pregnancy: prospective follow-up study. Reprod Toxicol 36:98–103

    Article  CAS  PubMed  Google Scholar 

  44. Pastuszak AL, Schüler L, Speck-Martins CE, et al (1998) Use of misoprostol during pregnancy and Möbius’ syndrome in infants. N Engl J Med 338:1881–1885

    Article  CAS  PubMed  Google Scholar 

  45. Hoeltzenbein M, Elefant E, Vial T, et al (2012) Teratogenicity of mycophenolate confirmed in a prospective study of the European Network of Teratology Information Services. Am J Med Genet A158A:588–596

    Article  PubMed  Google Scholar 

  46. Le Ray C, Coulomb A, Elefant E, et al (2004) Mycophenolate mofetil in pregnancy after renal transplantation: a case of major fetal malformations. Obstet Gynecol 103:1091–1094

    Article  PubMed  Google Scholar 

  47. Tomson T, Battino D (2012) Teratogenic effects of antiepileptic drugs. Lancet Neurol 11:803–813

    Article  CAS  PubMed  Google Scholar 

  48. Hunt S, Russell A, Smithson WH, et al (2008) Topiramate in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology 71:272–276

    Article  CAS  PubMed  Google Scholar 

  49. Margulis AV, Mitchell AA, Gilboa SM, et al (2012) Use of topiramate in pregnancy and risk of oral clefts. Am J Obstet Gynecol 207:405

    Article  PubMed Central  PubMed  Google Scholar 

  50. Ornoy A, Zvi N, Arnon J, et al (2008) The outcome of pregnancy following topiramate treatment: a study on 52 pregnancies. Reprod Toxicol 25:388–389

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre de référence sur les agents tératogènes (CRAT), hôpitaux universitaires Est Parisien (AP-HP), hôpital Armand Trousseau, 26, avenue du Dr Netter, F-75571, Paris cedex 12, France

    E. Elefant

Authors
  1. E. Elefant
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. Elefant.

About this article

Cite this article

Elefant, E. Médicaments et grossesse : aide pour l’échographiste. Rev. med. perinat. 6, 39–48 (2014). https://doi.org/10.1007/s12611-014-0270-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12611-014-0270-z

Mots clés

Keywords

Search

Navigation